We are live on ! Find out more
VRCA icon

Verrica Pharmaceuticals
VRCA

40 hedge funds and large institutions have $97M invested in Verrica Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 4

41% more capital invested

Capital invested by funds: $68.8M → $97M (+$28.2M)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

0.14% more ownership

Funds ownership: 3.29% → 3.43% (+0.14%)

0% more funds holding

Funds holding: 40 → 40 (0)

Holders
40
Holders Change
–
Holders Change %
0%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
18
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.49M
2
KCM
Kornitzer Capital Management
Kansas
+$1.38M
3
Bank of America
Bank of America
North Carolina
+$945K
4
EIM
Essex Investment Management
Massachusetts
+$596K
5
Northern Trust
Northern Trust
Illinois
+$464K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$791K
2
PVI
Pura Vida Investments
New York
-$521K
3
Morgan Stanley
Morgan Stanley
New York
-$159K
4
JP Morgan Chase
JP Morgan Chase
New York
-$115K
5
UBS Group
UBS Group
Switzerland
-$23.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$50K +$52.7K +457 New
New York State Common Retirement Fund
27
New York State Common Retirement Fund
New York
$37K – – –
Wells Fargo
28
Wells Fargo
California
$32K – – –
Citigroup
29
Citigroup
New York
$31K +$14K +121 +73%
JP Morgan Chase
30
JP Morgan Chase
New York
$28K -$115K -999 -79%
Morgan Stanley
31
Morgan Stanley
New York
$25K -$159K -1,382 -86%
BNP Paribas Financial Markets
32
BNP Paribas Financial Markets
France
$24.4K +$26.1K +226 New
UBS Group
33
UBS Group
Switzerland
$24K -$23.2K -201 -48%
Legal & General Group
34
Legal & General Group
United Kingdom
$20K +$11.5K +100 +112%
SO
35
STRS Ohio
Ohio
$18K – – –
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$12K +$461 +4 +4%
SMFS
37
Squar Milner Financial Services
California
$10K – – –
TRCT
38
Tower Research Capital (TRC)
New York
$3K -$7.84K -68 -73%
AIP
39
Ameritas Investment Partners
Nebraska
$3K – – –
LTFS
40
Ladenburg Thalmann Financial Services
Florida
$1K – – –
SFM
41
Sphera Funds Management
Israel
– -$791K -9,700 Closed
PVI
42
Pura Vida Investments
New York
– -$521K -6,392 Closed
CSS
43
Cubist Systematic Strategies
Connecticut
– -$3K -43 Closed
Bank of Montreal
44
Bank of Montreal
Ontario, Canada
– -$1K -8 Closed
1
2

VRCA Hedge Fund Activity: Q1 2019 in Review

40 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2019, worth a combined $97M — up 41% from $68.8M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VRCA positions and 4 closed out — a net gain of 1 holder — while 18 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $2.49M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $791K sold.

  • 40 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $97M of Verrica Pharmaceuticals stock for Q1 2019, up 41% quarter-over-quarter.
  • 5 funds opened new Verrica Pharmaceuticals positions in Q1 2019 and 4 closed out, a net change of +1 holder.
  • The largest Verrica Pharmaceuticals buyer in Q1 2019 was BlackRock, an estimated $2.49M added.
  • The largest Verrica Pharmaceuticals seller in Q1 2019 was Sphera Funds Management, an estimated $791K sold.

Based on aggregated 13F filings for Q1 2019.